Literature DB >> 17079036

B-type natriuretic peptide and cardiac dysfunction in Duchenne muscular dystrophy.

Tayyab Mohyuddin, Irwin B Jacobs, Robert C Bahler.   

Abstract

Serum levels of B-type natriuretic peptide have moderate utility for detection of early ventricular dysfunction in adults and in experimental muscular dystrophy. To determine if B-type natriuretic peptide levels are useful in the detection of early left ventricular dysfunction in Duchenne muscular dystrophy patients, measurements were obtained in 21 patients being evaluated by echocardiography for left ventricular dysfunction. Two patients with clinical evidence of heart failure were excluded (mean B-type natriuretic peptide level of 352 pg/ml). Age range of the remaining 19 patients was 9-21 yrs. Fractional shortening was abnormal (<30%) in 14/19 and early diastolic tissue Doppler velocities were abnormal in 13/16. In these patients B-type natriuretic peptide levels were clearly normal (<30 pg/ml) in 15/19 and only mildly elevated (30-80 pg/ml) in 4/19. The 4 patients with mildly elevated B-type natriuretic peptide had significantly lower fractional shortening (12.6+/-5.9 versus 19.8+/-5.3, p<0.05). In conclusion, B-type natriuretic peptide levels are normal in the majority of Duchenne muscular dystrophy patients with asymptomatic left ventricular dysfunction and only mildly elevated when fractional shortening is markedly reduced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079036     DOI: 10.1016/j.ijcard.2006.07.163

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Duchenne Muscular Dystrophy Cardiomyopathy.

Authors:  Jonathan H Soslow; Meng Xu; James C Slaughter; Kimberly Crum; Joshua D Chew; W Bryan Burnette; Yan Ru Su; Kelsey Tomasek; David A Parra; Larry W Markham
Journal:  J Card Fail       Date:  2019-02-11       Impact factor: 5.712

2.  The correlation analysis of functional factors and age with duchenne muscular dystrophy.

Authors:  Il-Young Jung; Jong Hee Chae; Sue Kyung Park; Je Ho Kim; Jung Yoon Kim; Sang Joon Kim; Moon Suk Bang
Journal:  Ann Rehabil Med       Date:  2012-02-29

3.  The association between cardiac involvement and long-term clinical outcomes in patients with Duchenne muscular dystrophy.

Authors:  Jung-Joon Cha; In-Soo Kim; Jong-Youn Kim; Eui-Young Choi; Pil-Ki Min; Young Won Yoon; Byoung Kwon Lee; Bum-Kee Hong; Hyuck Moon Kwon; Han Eol Cho; Won Ah Choi; Seong-Woong Kang; Se-Joong Rim
Journal:  ESC Heart Fail       Date:  2022-05-17

4.  Cardiac assessment of patients with late stage Duchenne muscular dystrophy.

Authors:  E A P van Bockel; J S Lind; J G Zijlstra; P J Wijkstra; P M Meijer; M P van den Berg; R H J A Slart; L P H J Aarts; J E Tulleken
Journal:  Neth Heart J       Date:  2009-06       Impact factor: 2.380

5.  Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.

Authors:  Larry W Markham; Jonathan H Soslow; Aryaz Sheybani; Kim Crum; Frank J Raucci; William B Burnette
Journal:  Pediatr Res       Date:  2021-08-24       Impact factor: 3.756

6.  Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers.

Authors:  Steven Schade van Westrum; Lukas Dekker; Rob de Haan; Erik Endert; Ieke Ginjaar; Marianne de Visser; Anneke van der Kooi
Journal:  BMC Neurol       Date:  2013-07-16       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.